Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cryo-activation and Pembrolizumab in Advanced NSCLC
NCT04793815Phase 2Completed
- Sponsor
- Centre hospitalier de l’Université de Montréal
- Start
- May 2021
- Primary completion
- Jun 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by Centre hospitalier de l’Université de Montréal. Primary endpoint: Best Overall Response Rate at 5 years. Started May 2021; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04793815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04793815.